Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis

Cancer

Volumn 121, Issue 13, 2015, Pages 2164-2174

  Kokabi, Nima ^a   Camacho, Juan C ^a   Xing, Minzhi ^a,b   El Rayes, Bassel F ^a   Spivey, James R ^a   Knechtle, Stuart J ^c   Kim, Hyun S ^a,b,d  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

efficacy; infiltrative hepatocellular carcinoma (HCC); overall survival; portal vein thrombosis; safety; time to progression; yttrium 90 (90Y) radioembolization

Indexed keywords

GLASS BASED Y 90; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; YTTRIUM;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; ASCITES; BONE MARROW TOXICITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CHILD PUGH SCORE; CLINICAL ARTICLE; FATIGUE; FEASIBILITY STUDY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; INTERNATIONAL NORMALIZED RATIO; LIVER CELL CARCINOMA; LIVER TOXICITY; MALE; NEPHROTOXICITY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION PNEUMONIA; RADIOEMBOLIZATION; TIME TO PROGRESSION; TUMOR GROWTH; ADVERSE EFFECTS; ARTIFICIAL EMBOLIZATION; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; DISEASE COURSE; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PORTAL VEIN; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME; VENOUS THROMBOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PORTAL VEIN; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VENOUS THROMBOSIS; YTTRIUM RADIOISOTOPES;

EID: 84931566293     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29275     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D., Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
2. Altekruse SF, McGlynn KA, Reichman ME., Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009; 27: 1485-1491.
3. Bosch FX, Ribes J, Diaz M, Cleries R,. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127 (5 suppl 1): S5-S16.
4. Parkin DM, Bray F, Ferlay J, Pisani P., Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
5. Llovet JM, Burroughs A, Bruix J., Hepatocellular carcinoma. Lancet. 2003; 362: 1907-1917.
6. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G., Current management strategy of hepatocellular carcinoma. World J Gastroenterol. 2009; 15: 3210-3216.
7. Demirjian A, Peng P, Geschwind JF, et al., Infiltrating hepatocellular carcinoma: seeing the tree through the forest. J Gastrointest Surg. 2011; 15: 2089-2097.
8. Kanematsu M, Semelka RC, Leonardou P, Mastropasqua M, Lee JK., Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging. 2003; 18: 189-195.
9. Llovet JM, Bru C, Bruix J., Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999; 19: 329-338.
10. Lopez RR Jr, Pan SH, Hoffman AL, et al., Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch Surg. 2002; 137: 653-657.
11. Jang ES, Yoon JH, Chung JW, et al., Survival of infiltrative hepatocellular carcinoma patients with preserved hepatic function after treatment with transarterial chemoembolization. J Cancer Res Clin Oncol. 2013; 139: 635-643.
12. Salem R, Thurston KG, Carr BI, Goin JE, Geschwind JF., Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002; 13 (9 pt 2): S223-S229.
13. Hilgard P, Hamami M, Fouly AE, et al., Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010; 52: 1741-1749.
14. Mazzaferro V, Sposito C, Bhoori S, et al., Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: a phase 2 study. Hepatology. 2013; 57: 1826-1837.
15. Sangro B, Carpanese L, Cianni R, et al., Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona Clinic Liver Cancer stages: a European evaluation. Hepatology. 2011; 54: 868-878.
16. Salem R, Lewandowski RJ, Mulcahy MF, et al., Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010; 138: 52-64.
17. Inarrairaegui M, Thurston KG, Bilbao JI, et al., Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010; 21: 1205-1212.
18. Kulik LM, Carr BI, Mulcahy MF, et al., Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008; 47: 71-81.
19. Kokabi N, Galt JR, Xing M, et al., A simple method for estimating dose delivered to hepatocellular carcinoma after yttrium-90 glass-based radioembolization therapy: preliminary results of a proof of concept study. J Vasc Interv Radiol. 2014; 25: 277-287.
20. Salem R, Lewandowski RJ, Gates VL, et al., Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011; 22: 265-278.
21. Prajapati HJ, Rafi S, Edalat F, Kooby DA, Kim HS., Safety and efficacy of a circumferential clip-based vascular closure device in cirrhotic and coagulopathic patients with hepatocellular carcinoma after doxorubicin drug-eluting beads transarterial chemoembolization. Cardiovasc Intervent Radiol. 2014; 37: 664-670.
22. US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Accessed February 11, 2014.
23. Lencioni R, Llovet JM., Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30: 52-60.
24. Bruix J, Sherman M, Llovet JM, et al., Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001; 35: 421-430.
25. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56: 908-943.
26. Bruix J, Sherman M., Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53: 1020-1022.
27. Kennedy AS, McNeillie P, Dezarn WA, et al., Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys. 2009; 74: 1494-1500.
28. Maor Y, Malnick S., Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol. 2013; 2013: 815105.